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ABSTRACT 
Background: Strontium ranelate (SR) is a new antiosteoporotic agent with 
antiresorptive and bone-forming properties. The exact mechanism by which SR 
exerts its effects is not clearly understood. Bone resorption requires interaction 
between osteoblasts and osteoclasts. Osteoblasts produce a ligand for receptor 
activator of nuclear factor-~cB (RANK). They also secrete osteoprotegerin, a 
decoy protein that blocks the interaction of RANK with its ligand, thereby in- 
hibiting the differentiation and activity of osteoclasts. SR also has been associ- 
ated with osteoblast proliferation and decreased osteoblast-induced osteoclast 
differentiation via increased osteoprotegerin messenger RNA expression in 
human osteoblasts. 
Objective: The aim of this study was to investigate the relationship between 
SR treatment and serum osteoprotegerin concentration i women with post- 
menopausal osteoporosis (PMO). 
Methods: This open, prospective study was conducted in women admitted 
to the outpatient endocrinology clinic of Baskent University Faculty of Medicine, 
Adana Medical Center, Ankara, Turkey, for the evaluation of PMO. Women with 
PMO who enrolled were administered elemental calcium 1000 mg/d and vitamin D 
800 IU/d for 1 month before the study period. After obtaining baseline serum 
samples for determining osteoprotegerin concentrations, patients were assigned 
to the treatment or control groups at a 5:2 ratio and SR 2 g/d was administered to
the treatment group. The control group continued to receive only calcium 
and vitamin D. Serum osteoprotegerin concentration was measured again after 
3 months of treatment. 
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Results: Thirty-five women (treatment group: n = 25; mean [SD] age, 59.80 
[7.38] years; control group: n = 10; mean [SD] age, 56.60 [5.06] years) enrolled 
in the study. A total of 32 women--24 in the treatment group and 8 in the con- 
trol group--completed the study. Compared with baseline, mean [SD] serum 
osteoprotegerin concentration did not change significantly after 3 months in 
either the treatment group (4.91 [1.24] pmol/L vs 4.71 [1.19] pmol/L) or the con- 
trol group (5.36 [2.82] pmol/L vs 5.10 [2.19] pmol/L). 
Conclusion: The results of this small study found that serum osteoprotegerin 
concentrations were not significantly changed by SR treatment for 3 months 
among women with PMO. (Curt Ther Res Clin Exp. 2007;68:217-225) Copyright © 
2007 Excerpta Medica, Inc. 
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INTRODUCTION 
Strontium ranelate (SR) is a new (2004) antiosteoporotic agent that has antire- 
sorptive and bone-forming properties. It is composed of ranelic acid, which is an 
organic acid, and 2 atoms of stable strontium. There is experimental evidence 
that SR at low doses (_<4 mmol/kg • d -1) increases bone formation and decreases 
bone resorption, resulting in increased bone mass in healthy animals. 1The drug 
stimulates endosteal bone formation and increases trabecular bone volume. The 
latter effects are independent of changes in serum parathyroid hormone (PTH) 
and 1,25-dihydroxyvitamin D 3 concentrations. 1-3 SR decreases the activity and 
differentiation of osteoclasts and induces osteoclast apoptosis in vitro. 4-7 How- 
ever, these effects are not complete, permitting the physiologic regulation of 
bone cells to continue. SR enhances the replication of preosteoblasts and stimu- 
lates DNA and bone collagen synthesis. 8,9 The exact mechanism by which SR 
exerts these effects is not understood. 
Recent data indicate that SR inhibits the differentiation of RAW cells, a 
murine model of osteoclasts, and human peripheral monocytes, both of which 
can differentiate in the presence of receptor activator of nuclear factor (NF)-~cB 
ligand (RANKL) in vitro. 6 
Bone resorption requires interaction between osteoblasts and osteoclasts. 
Osteoblasts produce RANKL, a ligand for the receptor activator of NF-~cB (RANK) on 
hematopoietic cells. In the presence of colony-stimulating factor-i, RANKL induces 
osteoclastogenesis. Osteoblasts also produce and secrete osteoprotegerin, a decoy 
protein that acts as a soluble receptor for RANKL. Osteoprotegerin blocks the inter- 
action of RANK with its ligand, RANKL, and inhibits the differentiation a d activity 
of osteoclasts. 1° The RANK/RANKL system is essential for mature osteoclast forma- 
tion and plays a critical role in T-cell-mediated osteoclastogenesis. 11,12 
Postmenopausal osteoporosis (PMO), an important and preventable health 
problem characterized by estrogen deficiency, results from an imbalance 
between bone resorption and formation and is the primary cause of fractures 
in elderly women. 13,14 During the postmenopausal period, osteoprotegerin con- 
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centration decreases due to declining estrogen concentration, and its effects on 
RANKL lessen, resulting in accelerated bone loss. 1° Levels of RANKL were also 
found to increase significantly on the surface of bone marrow cells of women in 
early postmenopause who are estrogen deficient. 15 
SR interacts with both spectrums of bone remodeling--formation a d 
resorption--indicating that the drug might act via a physiologic pathway. A 
recent in vitro study 16 found that SR promoted osteoblast proliferation and 
decreased osteoblast-induced osteoclast differentiation by increasing osteo- 
protegerin messenger RNA (mRNA) expression in human osteoblasts. 
The aim of this open, prospective study was to investigate the relationship 
between SR treatment and serum osteoprotegerin concentration i women 
with PMO. 
SUBJECTS AND METHODS 
The study participants were recruited among women admitted to the outpatient 
endocrinology clinic of Baskent University Faculty of Medicine, Adana Medical 
Center, Ankara, Turkey, for the evaluation of PMO. The local ethics committee 
approved the study protocol and, after a complete xplanation, written informed 
consent was obtained from each patient. 
The inclusion criteria were as follows: age >45 years; no menstruation within 
the last 12 months; >1 risk factor for osteoporotic bone fracture (eg, a family 
history of fracture, a personal history of fragility fracture, low body weight, and 
a loss of height)17; and a T value <2.5 at 1 of the central sites (ie, the femoral or 
lumbar region) as detected by dual energy x-ray absorptiometry (DEXA). 18,19 
Patients who had secondary osteoporosis, Paget's disease, multiple myeloma 
or bone metastasis, hepatic or renal dysfunction, or any chronic disabling dis- 
ease were excluded from the study. Additional exclusion criteria were the use 
of anabolic steroids, glucocorticoids, estrogen, calcitonin, thiazide diuretics, or 
vitamin D within the previous 6 months; calcium or phosphate supplements 
within 1 month; and bisphosphonates within 12 months. 
Baseline venous blood samples for determination of calcium, phosphorus, 
intact PTH, and 25-hydroxyvitamin D 3 concentrations were drawn into evacuated 
serum separator tubes (Vacuette, Greiner Bio-One, Kremsmuenster, Austria) after 
patients had fasted overnight. Twenty-four-hour inary calcium excretion was 
also measured for each patient. Thereafter, the patients were administered cal- 
cium 1000 mg/d and vitamin D 800 IU/d supplements for 1 month before the study 
period. 
At the end of that month, serum samples were obtained for the determina- 
tion of osteoprotegerin concentration and patients were assigned to the treat- 
ment or control groups at a 5:2 ratio. Both groups continued receiving elemen- 
tal calcium and vitamin D supplements, and SR 2 g/d was added to the regimen 
of the treatment group. Because oral calcium supplementation might interfere 
with SR absorption, the study patients were warned against administering SR 
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and calcium simultaneously. 2° Serum osteoprotegerin samples were collected 
again after 3 months of treatment. 
Serum calcium 21 and phosphorus 22levels were assayed by colorimetric meth- 
ods with a chemical autoanalyzer (Modular D/P, Roche Diagnostics, Mannheim, 
Germany) within 4 hours after collection. Intact PTH concentrations were calcu- 
lated using a solid-phase, 2-site chemiluminescent enzyme immunoassay on an 
Immulite analyzer (Diagnostic Products Corp., Los Angeles, California). The analy- 
sis of 25-hydroxyvitamin D 3 was done by radioimmunoassay (IDS Gamma-B 
25-Hydroxy Vitamin D RIA kit, Immuno Diagnostic Systems Ltd., Tyne and Wear, 
United Kingdom) using an antibody specific for 25-hydroxyvitamin D 3 with intra- 
and interassay CVs <8.5%. Urinary calcium was measured using the cresolphtha- 
lein complexone spectrophotometric method 21 and kinetic Jaffe reaction on a 
Hitachi 912 autoanalyzer (Roche Diagnostics Corp., Indianapolis, Indiana). Serum 
osteoprotegerin concentrations were determined using a sandwich-type enzyme- 
linked immunosorbent assay in a commercial kit (Immun Diagnostik AG, Bensheim 
and Biomedica, Wien, Austria). Intra- and interassay CVs were <10%, and the 
detection limit was 0.14 pmol/L. The manufacturer's stated intra-assay precisions 
are 10% to 8% and interassay precision is <10%. 
Statistical Analyses 
The power of the study to demonstrate a significant change in serum osteo- 
protegerin concentration was based on a previous study 23 reporting that the 
mean (SD) serum osteoprotegerin concentration was 4.4 (2.3) pmol/L in healthy 
women. Using a 2-sided P < 0.05 significance level and considering a 30% differ- 
ence as clinically significant, asample of 20 patients was needed to detect a 30% 
change in serum osteoprotegerin concentration with 80% power. Assuming a 
20% drop-out rate, a total of 25 patients were needed in the study. 24 
Statistical analyses were performed using SPSS for Windows, version 9.05 
(SPSS Inc., Chicago, Illinois). P < 0.05 was considered statistically significant. 
Standard escriptive analyses and paired and independent sample t tests were 
used where appropriate. 
RESULTS 
Thirty-five women (treatment group: n = 25, mean [SD] age, 59.80 [7.38] years; 
control group: n = 10, mean [SD] age, 56.60 [5.06] years) entered the study 
(Table I). One patient in the treatment group was withdrawn because of 
intractable nausea that was attributed to SR and 2 patients in the control group 
were lost to follow-up. Therefore, a total of 32 patients--24 in the treatment 
group and 8 in the control group--completed the study. 
For each patient, DEXA measurements and laboratory findings (serum con- 
centrations of calcium, phosphorus, intact PTH, and 25-hydroxyvitamin D3; 
24-hour urinary calcium excretion) were used to diagnose osteoporosis 
(Table I). 
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Table I. Baseline demographic and clinical characteristics of female patients with 
postmenopausal osteoporosis (N = 35). All data are mean (SD). 
Reference Treatment Group Control Group 
Characteristic Range (n = 25) (n = 10) P 
Age, y - 59.80 (7.38) 56.60 (5.06) 0.079 
Bone mineral density 
(T score) ~2.5 -3.34 (0.54) -3.02 (0.31) 0.092 
Serum calcium, 
mg/dL 8.40-10.20 9.62 (0.31) 9.65 (0.28) 0.80 
Serum phosphorus, 
mg/dL 2.70-4.50 3.78 (0.48) 3.78 (0.41) 0.98 
Serum intact 
parathyroid hormone, 
ng/L 20.00-70.00 55.25 (20.84) 57.92 (16.58) 0.72 
Serum 
25-hyd roxyvitamin D3, 
ng/mL 10.00-40.00 17.84 (8.22) 14.85 (5.60) 0.30 
24-Hour urinary 
calcium excretion, 
mg/d - 150.60 (84.33) 115.0 (65.36) 0.24 
Compared with baseline, mean [SD] serum osteoprotegerin concentration 
did not change significantly after 3 months in either the treatment group 
(4.91 [1.24] pmol/L vs 4.71 [1.19] pmol/L) or the control group (5.36 [2.82] pmol/L 
vs 5.10 [2.19] pmol/L) (Table If). Similarly, the change in serum osteoprotegerin 
concentration from baseline to 3 months was not significantly different in 
the treatment group compared with the control group (0.20 [0.81] pmol/L vs 
0.26 [0.81] pmol/L, respectively). 
Table II. Osteoprotegerin concentration at baseline and after 3 months of treatment 




Group Concentration, pmol/L Concentration, pmol/L P 
Treatment (n = 24) 4.91 (1.24) 4.71 (1.19) 0.24 
Control (n = 8) 5.36 (2.82) 5.10 (2.19) 0.39 
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DISCUSSION 
SR has been found to increase vertebral bone mineral density and to signifi- 
cantly reduce the prevalence of vertebral fractures among postmenopausal 
women. 25-27 Available antiosteoporotic drugs, such as estrogens and bisphos- 
phonates, inhibit bone remodeling by reducing bone formation and resorp- 
tion. 28 This mechanism of action has been associated with adverse events. 
Experimental studies have found that severely suppressed bone remodeling 
may cause decreased bone elasticity in the long-term and may impair the 
repair of microdamage. 29-31 However, SR decreases bone resorption and in- 
creases bone formation, both of which remain within a physiologic range, with- 
out interrupting bone remodeling. 8 Considering the NF-~B-osteoprotegerin 
axis, which consists of osteoblastic signals that are the final mediators of 
osteoclastogenesis, we searched for a link between SR and osteoprotegerin. 1° 
In their prospective study, Meunier et a] 26 recently reported that after 
3 months of SR treatment in postmenopausal women, bone alkaline phos- 
phatase concentration peaked and C cross-linking telopeptide of type I colla- 
gen decreased. Therefore, we decided to measure serum osteoprotegerin 
concentrations after 3 months of SR treatment in postmenopausal women 
with osteoporosis. 
We found no significant change in serum osteoprotegerin concentration after 
SR treatment for 3 months. The results of our study contradict those of the in 
vitro study by Brennan et a116 that found an increase in osteoprotegerin mRNA 
concentration with SR in osteoblasts. The highly dynamic and complex nature 
of bone metabolism ay be a rational explanation for our findings and makes 
the contribution of many other factors likely (eg, genes determining osteoblast 
differentiation and function, local and systemic growth factors, cytokines). 14
The course of action might occur differently at various tissue sites, and our 
measurement of osteoprotegerin o ly in serum is possibly a limitation of our 
study. We did not determine the presence of changes in osteoprotegerin con- 
centration in bone tissue, because we thought hat bone biopsy would have 
been an excessively invasive procedure in this study. Experimental studies to 
address this question are needed. 
Our patients had relatively low serum concentrations of 25-hydroxyvitamin 
D 3 and high-normal or mildly elevated serum PTH concentrations at baseline. 
These findings might be associated with seasonal changes in vitamin D and PTH 
concentrations, as the study was carried out in winter. 32 Although neither vita- 
min D nor PTH is reported to affect he actions of SR, we supplied adequate cal- 
cium and vitamin D prior to the study period. 1-3 
Little is known about the mechanism of action of SR. Calcium-sensing 
receptors in bone cells have been found to be activated by strontium. This 
may result in inositol phosphate 3 production and mitogen-activated protein 
kinase signaling. 33,34 Another possible effect of SR on osteoblasts might be 
the induction of cyclooxygenase-2 expression and prostaglandin E 2 produc- 
tion through activation of the extracellular signal-regulated kinase signaling 
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pathway. 35 Neither of these mechanisms has been clearly demonstrated.  8 
Osteoprotegerin concentration i  bone tissue should be investigated before mak- 
ing a decision as to the role of osteoprotegerin in the mechanism of action of SR. 
CONCLUSIONS 
This small study found that serum osteoprotegerin concentrat ions were not sig- 
nificantly changed by SR treatment for 3 months among women with PMO. 
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